Kingchem (Liaoning) Life Science Co., Ltd. Class A

Kingchem (Liaoning) Life Science Co., Ltd. Class A

SSZSE:301509
24.78
CNY
-0.32
(-1.27%)
0.38EPS
83.11P/E
3.76BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.27
5.92
6.64
6.12
7.93
7.64
4.12
5.31
5.13
Basic EPS, GAAP
0.38
0.83
0.84
0.94
1.79
1.73
0.32
0.87
0.38
Free Cash Flow per Basic Share
-0.21
0.39
0.27
-1.1
1.27
0.82
0.84
1.07
- -
Dividend per Share
0.04
0.06
0.09
0.55
0.05
0.02
0.57
0.4
- -
Book Value per Share
2.98
3.62
5.72
7.79
9.73
18.02
17.84
18.32
17.73
Tangible Book Value per Share
2.89
3.53
5.61
7.25
9.18
17.62
17.45
17.95
17.37
Basic Weighted Avg Shares
70
70
70
90
90
100
121
120
120
Sales/Revenue/Turnover
301
415
464
549
717
767
497
639
616
Operating Margin (%)
12.95
18.21
19.25
20.43
25.39
27.34
5.97
17.75
7.96
Depreciation Expense
30
32
36
45
54
68
67
62
- -
Net Income, GAAP
27
58
59
85
161
174
39
105
45
Effective Tax Rate (%)
11.22
16.33
14.22
15.32
16.68
14.67
1.67
13.33
13.6
Profit Margin (%)
8.88
14
12.69
15.4
22.53
22.64
7.77
16.39
7.33
Working Capital
107
156
297
385
488
1,736
1,411
1,518
1,607
LT Debt
25
23
24
40
51
5
3
2
2
Total Equity
270
327
516
704
879
2,171
2,149
2,207
2,136
Return on Invested Capital (%)
- -
15.73
12.62
12.55
18.69
11.05
1.76
4.83
2.11
Return on Capital (%)
- -
17.71
14.46
13.52
19.01
11.14
1.8
4.81
2.1
Return on Common Equity (%)
- -
19.5
13.97
13.86
20.4
11.38
1.79
4.81
2.09

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
120
120
120
Market Capitalization
4,913
3,663
3,764

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,638
1,760
1,741
Cash, Cash Equivalents & STI
1,106
1,146
920
Accounts Receivable, Net
120
109
111
Inventories
145
164
164
Total Current Liabilities
99
131
134
Payables & Accruals
- -
- -
- -
ST Debt
1
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
41.97%
2.71%
Free Cash Flow
- -
-161.9%
27.34%
Net Income, GAAP
- -
47.13%
171.46%
Sales/Revenue/Turnover
- -
9.84%
28.64%
Total Cash Common Dividend
- -
711.21%
-30.05%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
124
138
125
110
497
2025
176
172
- -
152
639
2026
148
161
155
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.13
0.06
-0.01
0.32
2025
0.39
0.2
- -
0.01
0.87
2026
0.14
0.11
0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.58
- -
-0.01
0.57
2025
- -
- -
- -
- -
0.4
2026
- -
- -
- -
- -
- -

Company Description

CEO
Fu Min Wang
Full Time Employees
690
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Fuxin China
IPO Date
Aug 3, 2023
Business
Kingchem (Liaoning) Life Science Co., Ltd. is a contract development and manufacturing organization (CDMO) that provides customized chemical synthesis, process development, and commercial-scale manufacturing solutions for the global life sciences, pharmaceutical, agrochemical, and specialty chemical industries. The company specializes in advanced fluorine chemistry and hazardous reaction processing, delivering research, development, and production services across the lifecycle of small molecule therapeutics. Its core offerings and product lines include pharmaceutical intermediates and building blocks, such as fluorinated aromatics, fluorinated heterocycles, trifluoromethyl and difluoromethyl derivatives, chiral intermediates, and advanced active pharmaceutical ingredient (API) precursors; agrochemical fine chemicals and active intermediates for fungicides, herbicides, and insecticides; specialty electronic chemicals and fluorinated functional materials for high-technology applications; custom synthesis and contract manufacturing services, encompassing chemical route design, process optimization, safety assessment, scale-up synthesis, and both non-GMP and cGMP-compliant commercial production; and specialized technical engineering services, including continuous flow micro-reaction technology, cryogenic reactions, high-pressure hydrogenation, and hazardous fluorination reactions. The company serves global innovator pharmaceutical companies, multinational agrochemical enterprises, and biotechnology firms across China, North America, Europe, and the Asia-Pacific region. Founded in 2009 and headquartered in Fuxin, Liaoning Province, China, Kingchem (Liaoning) Life Science Co., Ltd. operates primary manufacturing facilities in Fuxin, research and technical support facilities in Dalian, and international customer service and commercialization networks through overseas affiliates in the United States. In recent developments, the company completed its initial public offering on the ChiNext board of the Shenzhen Stock Exchange (SZSE: 301509) in August 2023 to fund large-scale manufacturing expansion and technical capability upgrades. Operationally, the company has expanded its multi-purpose cGMP production lines and advanced fluorochemical continuous-flow engineering capacity at its Fuxin manufacturing hub, broadened strategic supply collaborations with global top-tier innovator pharmaceutical and crop protection clients, and enhanced its high-potency compound handling and green chemistry process optimization platforms to support commercial-scale pipeline projects.